Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A thymic epithelial neoplasm characterized by the presence of spindle and/or oval neoplastic epithelial cells. Lymphocytic infiltration is minimal or absent. It may be associated with myasthenia gravis or pure red cell aplasia. The majority of cases occur in the anterior mediastinum as Masaoka stage I tumors. Approximately 20% of the cases occur as stage II or stage III tumors. Type A thymoma generally behaves as a benign tumor and the overall survival is reported to be 100% at 5 and 10 years.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for thymoma type A.
14 publications have been identified in PubMed for thymoma type A. Research spans Case Report / Case Series (36%), Basic Science / Preclinical (36%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 36% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 4:22 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
5 |
36% |
Research summaries | 2 | 14% |
Disease patterns and progression | 1 | 7% |
New treatment approaches | 1 | 7% |
Yu XT (2025). [PMID: 40328968](https://pubmed.ncbi.nlm.nih.gov/40328968/). *Genes and immunity*. [Gene Therapy / Novel Therapeutics]
Wang XX (2025). [PMID: 40083873](https://pubmed.ncbi.nlm.nih.gov/40083873/). *Frontiers in oncology*. [Case Report / Case Series]
Ishida H (2025). [PMID: 40631010](https://pubmed.ncbi.nlm.nih.gov/40631010/). *JTCVS open*. [Basic Science / Preclinical]
Roden AC (2025). [PMID: 40044361](https://pubmed.ncbi.nlm.nih.gov/40044361/). *Mayo Clinic proceedings*. [Review / Meta-Analysis]
Haas CB (2025). [PMID: 40637693](https://pubmed.ncbi.nlm.nih.gov/40637693/). *Journal of the National Cancer Institute*. [Epidemiology / Natural History]
Nishizaki Y (2025). [PMID: 40044170](https://pubmed.ncbi.nlm.nih.gov/40044170/). *[Rinsho ketsueki] The Japanese journal of clinical hematology*. [Review / Meta-Analysis]
Suster DI (2025). [PMID: 40666531](https://pubmed.ncbi.nlm.nih.gov/40666531/). *Mediastinum (Hong Kong, China)*. [Basic Science / Preclinical]
Taghiyev ZT (2024). [PMID: 38988820](https://pubmed.ncbi.nlm.nih.gov/38988820/). *The Thoracic and cardiovascular surgeon reports*. [Case Report / Case Series]
Perrino M (2024). [PMID: 38629065](https://pubmed.ncbi.nlm.nih.gov/38629065/). *Frontiers in immunology*. [Basic Science / Preclinical]
Zargar S (2024). [PMID: 38783232](https://pubmed.ncbi.nlm.nih.gov/38783232/). *BMC neurology*. [Case Report / Case Series]